S-1/A: Coeptis Therapeutics Files Amendment to S-1 Registration for Resale of Common Stock

Coeptis Therapeutics is filing an amendment to its S-1 registration statement to allow selling stockholders to resell up to 3,919,349 shares of common stock.

Summary

• Coeptis Therapeutics Holdings, Inc., a biopharmaceutical and technology company, has filed an amendment to its S-1 registration statement.
• The filing relates to the resale of up to 3,919,349 shares of the company's common stock by selling stockholders.
• This includes 100,000 shares held directly or indirectly by selling stockholders, up to 3,737,472 shares that may be issued to YA II PN, LTD. (Yorkville) under a Standby Equity Purchase Agreement (SEPA), and 81,877 shares issued to Yorkville in connection with the partial conversion of an outstanding convertible note.
• The company will not receive any proceeds from the sale of these shares by the selling stockholders, but may receive up to $20 million from sales of common stock to Yorkville under the SEPA.
• The document details recent developments including a Series A offering that raised $10 million, the SEPA with Yorkville for up to $20 million, a reverse stock split at a ratio of 1-for-20, and the acquisition of an AI-powered marketing software platform.
• The company's growth strategy involves portfolio optimization, strategic partnerships, and business development.
• The company currently has six employees.
• The company's common stock is listed on the Nasdaq Capital Market under the symbol COEP.
• On April 2, 2025, the last reported sales price of the company's common stock was $9.48 per share.
• The company is an emerging growth company and is subject to reduced public company reporting requirements.

Sentiment

Score: 5

Explanation: The document presents a mix of positive and negative aspects. While there are potential funding opportunities and strategic initiatives, the company's history of losses and going concern uncertainty temper the overall sentiment.

Positives

• The company has secured a Standby Equity Purchase Agreement (SEPA) with Yorkville for up to $20 million, providing potential funding.
• The company completed a Series A offering, raising $10 million.
• The company acquired an AI-powered marketing software platform, expanding its technology offerings.
• The company has a growth strategy focused on portfolio optimization and strategic partnerships.

Negatives

• The company will not receive any proceeds from the sale of shares by the selling stockholders.
• The company has a history of losses and expects to incur losses in the future.
• There is a substantial doubt about the company's ability to continue as a going concern.
• The company needs to obtain financing in order to continue its operations.

Risks

• The company may not be able to successfully implement its growth strategy.
• The company may have difficulties managing its anticipated growth.
• The company may not be able to initiate and complete preclinical studies and clinical trials for its product candidates.
• The company may not be able to obtain and maintain third-party relationships.
• The company may face difficulties in integrating the use of the NexGen AI Affiliates Network platform.
• The drug development and approval process is uncertain, time-consuming, and expensive.
• Competition in the biotechnology and pharmaceutical industries may result in competing products.
• The company may not be able to maintain its listing on the Nasdaq Capital Market.

Future Outlook

The company expects to use the net proceeds from sales of its Common Stock to Yorkville, if any, under the SEPA for working capital and general corporate purposes.

Industry Context

The document references the CAR T-cell therapy market, which is expected to reach $20.56 billion by 2029, representing a compound annual growth rate (CAGR) of 31.6% during the forecast period from 2022 to 2029.

Stakeholder Impact

• Shareholders may experience dilution due to the potential issuance of shares under the SEPA.
• The company's ability to execute its business plan and develop its product candidates will impact employees, customers, and suppliers.

Next Steps

• The company intends to focus on how to utilize the NexGenAI Affiliates Network platform as a source of revenue.
• The company will continue to evaluate, prioritize, optimize, and make appropriate changes in its pipeline portfolio.
• The company will focus on expanding its existing pipeline through establishing strategic partnerships.
• The company is actively seeking partnerships and/or strategic collaborations with companies that share in its vision for its therapeutic focus and/or its focus on technology expansion.

Key Dates

Keywords

common stock, Coeptis Therapeutics, registration statement, SEPA, Yorkville, Series A Preferred Stock, reverse stock split, biopharmaceutical, technology, clinical trials, FDA, intellectual property, financing